Kenai Therapeutics: Valuation, Funding & Investors
Kenai Therapeutics is a clinical-stage biotechnology company pioneering next-generation approaches to cure neurological conditions. The company develops off-the-shelf, allogeneic neuron replacement and gene-modified cell therapies, including RNDP-001 for idiopathic Parkinson's disease, and partners with FUJIFILM Cellular Dynamics for scalable, cryopreserved manufacturing.
Leadership & Board
- Current Number of Employees
- 43
- Current LinkedIn Followers
- 7,518
Latest Estimated Valuation
- Total Amount Raised
- $8M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $8M
- Latest Funding Round
- Investment
Employee Trend
Kenai Therapeutics had 43 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Kenai Therapeutics had 7,518 followers as of November 16, 2026. The number of followers increased by 21 (0.28%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 05, 2026 | Investment | $8.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| California Institute for Regenerative Medicine | Investment |
Similar Companies
A snapshot of private companies similar to Kenai Therapeutics, helping you discover and navigate related company profiles.







